<DOC>
	<DOCNO>NCT00104247</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy Phenoptin™ ( sapropterin dihydrochloride ) reduce blood phenylalanine ( Phe ) level subject phenylketonuria .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Phenoptin™ Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels</brief_title>
	<detailed_description />
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>8 year age old Received least 7 8 schedule dos Study PKU 001 Responsive Phenoptin™ Study PKU001 , define reduction blood Phenylalanine level &gt; /=30 % compare baseline Blood Phenylalanine level &gt; /=450 μmol/L screen Willing able provide write informed consent , case subject age 18 , provide write assent ( require ) write informed consent parent legal guardian , nature study explain Negative urine pregnancy test screening ( female childbearing potential ) Male Female subject childbearing potential ( sexually active ) must use acceptable birth control measure , determine investigator , willing continue use acceptable birth control measure participate study Willing able comply study procedure Willing continue current diet unchanged participate study Perceived unreliable unavailable study participation , age 18 , parent legal guardian perceive unreliable unavailable Use investigational agent Phenoptin™ within 30 day prior screen , requirement investigational agent investigational vaccine prior completion schedule study assessment Pregnant breastfeeding , consider pregnancy ALT &gt; 5 time upper limit normal ( i.e. , Grade 3 high base World Health Organization Toxicity Criteria ) screen Concurrent disease condition would interfere study participation safety ( e.g. , seizure disorder , oral steroiddependent asthma condition require oral parenteral corticosteroid administration , insulindependent diabetes , organ transplantation recipient ) Serious neuropsychiatric illness ( e.g. , major depression ) currently medical management Requirement concomitant treatment drug know inhibit folate synthesis ( e.g. , methotrexate ) Concurrent use levodopa Clinical diagnosis primary BH4 deficiency</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Phenylalanine Hydroxylase</keyword>
</DOC>